Serotonin 5-hydroxytryptamine2A receptor activation suppresses tumor necrosis factor-α-induced inflammation with extraordinary potency

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 2, 2008, Pages 316-323

  Yu, Bangning ^a   Becnel, Jaime ^a   Zerfaoui, Mourad ^a   Rohatgi, Rasika ^a   Boulares, A Hamid ^a   Nichols, Charles D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG DESIGN; DRUG POTENCY; GENE EXPRESSION REGULATION; IC 50; INFLAMMATION; MALE; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RAT; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA;

ACTIVE TRANSPORT, CELL NUCLEUS; AMPHETAMINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 54349110896     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143461     Document Type: Article

References (40)

1. Akiyoshi T, Zhang Q, Inoue F, Aramaki O, Hatano M, Shimazu M, Kitajima M, Shirasugi N, and Niimi M (2006) Induction of indefinite survival of fully mismatched cardiac allografts and generation of regulatory cells by sarpogrelate hydrochloride. Transplantation 82:1051-1059.
2. Arzt E, Costas M, Finkielman S, and Nahmod VE (1991) Serotonin inhibition of tumor necrosis factor-alpha synthesis by human monocytes. Life Sci 48:2557-2562.
3. Blankenberg S, Barbaux S, and Tiret L (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170:191-203.
4. Ckless K, van der Vliet A, and Janssen-Heininger Y (2007) Oxidative-nitrosative stress and post-translational protein modifications: implications to lung structurefunction relations. Arginase modulates NF-kappaB activity via a nitric oxide-dependent mechanism. Am J Respir Cell Mol Biol 36:645-653.
5. Cloëz-Tayarani I, Petit-Bertron AF, Venters HD, and Cavaillon JM (2003) Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors. Int Immunol 15:233-240.
6. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, and Maniatis T (1995) Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9:899-909.
7. Dunn AJ, Swiergiel AH, and de Beaurepaire R (2005) Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29: 891-909.
8. Guo Z, Shao L, Du Q, Park KS, and Geller DA (2007) Identification of a classic cytokine-induced enhancer upstream in the human iNOS promoter. FASEB J 21:535-542.
9. Guzik TJ, Korbut R, and Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469-487.
10. Hansson GK, Robertson AK, and Soderberg-Nauclér C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297-329.
11. Hughes JM, Arthur CA, Baracho S, Carlin SM, Hawker KM, Johnson PR, and Armour CL (2000) Human eosinophil-airway smooth muscle cell interactions. Mediators Inflamm 9:93-99.
12. Huntjens DR, Danhof M, and Della Pasqua OE (2005) Pharmacokinetic- pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 44:846-859.
13. Ito T, Ikeda U, Shimpo M, Yamamoto K, and Shimada K (2000) Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 102: 2522-2527.
14. Kim YK, Jung HG, Myint AM, Kim H, and Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104:91-95.
15. Kubera M, Maes M, Kenis G, Kim YK, and Lasoń W (2005) Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 134:251-258.
16. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237.
17. Little KY, Elmer LW, Zhong H, Scheys JO, and Zhang L (2002) Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol 61:436-445.
18. Marconi A, Darquenne S, Boulmerka A, Mosnier M, and D'Alessio P (2003) Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. Free Radic Biol Med 34:616-625.
19. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, and Nichols DE (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 49:5794-5803.
20. Miller KJ and Gonzalez HA (1998) Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells. Ann N Y Acad Sci 861:169-173.
21. Miller KJ, Mariano CL, and Cruz WR (1997) Serotonin 5HT2A receptor activation inhibits inducible nitric oxide synthase activity in C6 glioma cells. Life Sci 61:1819-1827.
22. Nagatomo T, Rashid M, Abul Muntasir H, and Komiyama T (2004) Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104:59-81.
23. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
24. Nichols DE, Frescas S, Marona-Lewicka D, and Kurrasch-Orbaugh DM (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N- diethyllysergamide (LSD). J Med Chem 45:4344-4349.
25. Nichols DE and Nichols CD (2008) Serotonin Receptors. Chem Rev 108:1614-1641.
26. Popa C, Netea MG, van Riel PL, van der Meer JW, and Stalenhoef AF (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751-762.
27. Reimold AM (2002) TNFalpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 1:377-392.
28. Roebuck KA and Finnegan A (1999) Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 66:876-888.
29. Roth BL and Chuang DM (1987) Multiple mechanisms of serotonergic signal transduction. Life Sci 41:1051-1064.
30. Roth BL, Nakaki T, Chuang DM, and Costa E (1986) 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther 238:480-485.
31. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, and Jazin E (2007) Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7:46.
32. Saucier C, Morris SJ, and Albert PR (1998) Endogenous serotonin-2A and -2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium: desensitization and down-regulation by serotonin. Biochem Pharmacol 56:1347-1357.
33. Shulgin A and Shulgin A (1991) PiHKAL. Transform Press, Berkeley.
34. Stefulj J, Jernej B, Cicin-Sain L, Rinner I, and Schauenstein K (2000) mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 14:219-224.
35. Tracey D, Klareskog L, Sasso EH, Salfeld JG, and Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244-279.
36. Tweedie D, Sambamurti K, and Greig NH (2007) TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 4:378-385.
37. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
38. Williams RO, Paleolog E, and Feldmann M (2007) Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol 7:412-417.
39. Willins DL, Deutch AY, and Roth BL (1997) Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82.
40. Zerfaoui M, Suzuki Y, Naura AS, Hans CP, Nichols C, and Boulares AH (2008) Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction. Cell Signal 20:186-194.